LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") – a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines – announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This […]

(NASDAQ:ADAM), NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — Adamas Trust, Inc. (Nasdaq: ADAM) (the “Company” or “Adamas”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.23 per share on shares of its common stock for the quarter ending December 31, 2025. The dividend will be payable

(NYSE MKT:NCL), Fort Lawn, SC, Dec. 11, 2025 (GLOBE NEWSWIRE) — Northann Corp. (NYSE American: NCL) (the “Company” or “Northann”), today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) that the Company was not in compliance with the Exchange's continued listing standards under Section 1003(a)(i) of the NYSE American

(NYSE:ABR), UNIONDALE, N.Y., Dec. 11, 2025 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (“Arbor”) (NYSE: ABR) today announced that its subsidiary, Arbor Realty SR, Inc. (the “Issuer”), has priced an offering of $400 million aggregate principal amount of 8.50% Senior Notes due 2028 (the “Notes”) in a private offering to persons reasonably believed to be

(NASDAQ:DYN), WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of

(NASDAQ:DVLT), PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) — via IBN– Datavault AI Inc. (NASDAQ: DVLT) (“Datavault AI” or the “Company”), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the “Datavault Board”) has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme

(NASDAQ:TERN), FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option

(NASDAQ:CRNX), SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). “Dosing the

(NASDAQ:NTSK), ARR increased 34% year-over-year to $754 million Q3 revenue increased 33% year-over-year to $184.2 million Surpassed $1 billion in Remaining Performance Obligations, reflecting 41% year-over-year growth Q3 net cash provided by operating activities was $11.2 million, representing 6% of revenue Q3 free cash flow was $10.6 million, representing a positive 6% free cash flow

(NasdaqGM:BBOT), SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT